Features of an integrated approach to the treatment of benign diseases of the mammary glands in patients with overweight

Abstract

The increase in the incidence of benign breast diseases in women is a significant medical and social problem. The leading risk factor for this pathology is overweight. Currently, there is no individual approach to the management of overweight women, which provides a high risk of developing dysplastic changes in the mammary gland.

Objective — to substantiate the effectiveness of the comprehensive approach to the treatment of fibrocystic mastopathy in overweight patients.

Material and methods. The study included 164 women with fibrocystic mastopathy and overweight. The treatment was aimed at reducing the body weight of patients while taking the drug Indinol Forto.

Results. Over a 6-month period, we managed to normalize the quality of life indicators, reduce the body weight of patients, and the size of pathological formations in the mammary glands.

Conclusion. The comprehensive approach to the treatment of patients with benign breast diseases of the mammary gland and overweight allows us achieving positive results.

Keywords

benign breast diseases / risk factors / quality of life assessment / selective modulator of estrogen receptors / reproductive age / complex treatment

References

[1] Беспалов В.Г., Травина М.Л. Фиброзно-кистозная болезнь и риск рака молочной железы (обзор литературы). Опухоли женской репродуктивной системы. 2015; (4): 58-70.

[2] Корженкова Г.П. Фиброзно-кистозная мастопатия: вариант нормы или болезнь? Онкогинекология. 2012; (3): 46-55.

[3] Ласачко С.А. Современные представления о дисгормональных заболеваниях молочных желез (обзор литературы). Новообразование. 2017; 16 (1): 29-35.

[4] Сметник А.А., Сметник В.П., Киселев В.И. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы. Акушерство и гинекология. 2017; (2): 106-12.

[5] Радзинский В.Е. Медицина молочной железы и гинекологические заболевания. М.: Status Praesens; 2017.

[6] Солодко В.А., Рожкова Н.И. Диффузные доброкачественные заболевания молочных желез. Диагностика и лечение. М.: Спец. изд-во мед. книг; 2012.

[7] Серов В.Н., Тагиева Т.Т. Доброкачественные заболевания молочных желез. Гинекологическая эндокринология. М.: МЕДпресс-информ; 2015.

[8] Высоцкая И.В., Летягин В.П., Черенков В.Г. и др. Клинические рекомендации РООМ по профилактике РМЖ, дифференциальной диагностике, лечению предопухолевых и доброкачественных заболеваний молочных желез. М.; 2015.

[9] Samali E., Trichopoulos D., Lagiou A. et al. The hormonal profile of benign breast disease. Br. J. Cancer. 2013; 108 (1): 199-204.

[10] Von Karsa L., Arrosi S. Development and implementation of guidelines for quality assurance in breast cancer screening: The European experience. Salud. Publica Mex. 2013; 55 (3): 318-28.

[11] Zavoloka A.V. Benign breast tumors diagnostic recent advances. J. Health. Sci. 2013; 3 (10): 665-74.

[12] Marconett C.N., Singhal A.K., Sundar S.N., Firestone G.L. Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human brest cancer cells. Mol. Cell. Endocrinol. 2012; 363 (1-2): 74-84.

RIGHTS & PERMISSIONS

Eco-Vector